Clinical Trial Update: TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC) [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1 study of the experimental agent TGRX-326 for advanced non-small cell lung cancer conducted in China, currently ac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TGRX-326

Snippet

Sponsor: Shenzhen TargetRx Co., Ltd. | Conditions: Non-small Cell Lung Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING